Persistent viral infections such as HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) in humans, simian immunodefi ciency virus (SIV) in monkeys, and lymphocytic choriomeningitis virus (LCMV) in mice are associated with functional exhaustion of virus-specifi c CD8 + T cells ( 1 -3 ) . This defect in responding T cells is one of the primary reasons for the inability of the host to eliminate the persisting pathogen. Because many chronic viral infections cannot be cleared by antiviral therapy alone ( 4, 5 ) , therapeutic vaccination, which aims to enhance the patient ' s own antiviral immune response, has been considered as an alternative therapy. However, the effi cacy of such strategies has so far been disappointing ( 6 -9 ) . Recent work suggests that the decreased proliferative potential of virus-specifi c CD8 + T cells generated during chronic infection, and high viral load at the time of vaccination might explain the inefficient responses to therapeutic vaccination ( 6, 8, 10 -12 ) . Thus, it is important to develop a therapeutic vaccine strategy to more eff ectively boost endogenous T cell responses to control persistent viral infections.
We have recently demonstrated that exhausted virus-specifi c CD8 + T cells up-regulate the inhibitory programmed death-1 (PD-1) during chronic infection with LCMV clone-13 (CL-13) ( 13 ) . Furthermore, in vivo blockade of PD-1 restores the function of virus-specifi c CD8 + T cells, resulting in enhanced viral clearance. Similarly, virus-specifi c CD8 + T cells signifi cantly up-regulate PD-1 expression during chronic infections such as HIV ( 14 -17 ) , HCV ( 18 -20 ) , and HBV in humans ( 21 ) and SIV in monkeys ( 22 ) . This expression correlates with viral load in the blood plasma in HIV-infected patients ( 14, 16, 17 ) and SIV-infected monkeys ( 22, 23 ) . Strikingly, blocking the interaction Importantly, combinatorial therapeutic vaccination (VV/GP33 + ␣ PD-L1) induced a signifi cant increase in the D b GP33-specifi c CD8 + T cell population (P < 0.01, 2 wk after therapy) over that in VV/WT + ␣ PD-L1 mice ( Fig. 1 A ) . This was sustained even after cessation of the ␣ PD-L1 treatment. In contrast, D b GP276-specifi c CD8 + T cell responses were not enhanced after combinatorial therapeutic vaccination compared with PD-L1 blockade of VV/WT-treated mice. Thus, vaccination with VV/GP33 enhanced CD8 + T cell response specifi c to gp33, but not gp276, indicating epitope-specifi c responses to therapeutic vaccination ( Fig. 1 B ) . Mice receiving combinatorial therapeutic vaccination showed accelerated clearance of virus from the blood compared with ␣ PD-L1 -treated mice vaccinated with VV/WT (P < 0.01, 2 wk and 3 wk after therapy; P < 0.05, 4 wk after vaccination; Fig. 1 C ) . Conversely, 75% of VV/WT-and 50% of VV/GP33-vaccinated mice remained viremic by 4 wk after vaccination. These results demonstrate that a combination of therapeutic vaccine and PD-L1 blockade synergistically enhanced expansion of CD8 + T cells and promoted clearance of persisting virus during chronic infection.
To examine whether combinatorial therapeutic vaccination resulted in increased responses in the tissues, we analyzed D b GP33-specifi c CD8 + T cell responses in diff erent tissues 2 wk after vaccination. In nonlymphoid tissues, such as liver and lung, as well as in lymphoid tissues, including spleen and LN, the combination of PD-L1 blockade with therapeutic vaccination resulted in a signifi cant increase in D b GP33-specifi c CD8 + T cells compared with control VV/WT vaccination, as well as VV/WT + ␣ PD-L1 (P < 0.05 in all tissues examined; Fig. 2, A and B ) . VV/GP33 therapeutic vaccination alone did not increase numbers of D b GP33-specifi c CD8 + T cells in the tissues (P > 0.05), which is consistent with our previous study ( 11 ) . Importantly, there was no comparable increase in D b GP276-specifi c CD8 + T cells between PD-L1 blockade and combinatorial therapeutic vaccine groups, confi rming that the synergistic eff ect on expansion of CD8 + T cells was epitope specifi c ( Fig. 2 C ) .
The aforementioned results suggested that PD-L1 blockade enhanced epitope-specifi c responses to therapeutic vaccination by rejuvenating circulating exhausted CD8 + T cells. Next, we assessed whether expansion of the D b GP33-specifi c CD8 + T cells after combinatorial therapeutic vaccination enhanced viral control in these tissues. Mice vaccinated with VV/GP33 alone demonstrated a reduction in viral titers in the tissues ( Fig. 3 A ; P < 0.05 in all tissues), despite no detectable increase in D b GP33-specifi c T cells in these mice ( Fig. 2, A and B ) . This suggests that therapeutic vaccination may lead to qualitative changes to the antigenspecifi c CD8 + T cells. As expected, PD-L1 blockade of VV/WT-vaccinated mice improved viral control ( Fig. 3 A ; P < 0.05 in all tissues). Importantly, combinatorial therapeutic vaccination induced a greater reduction in viral load in tissues including spleen, liver, lung, and LN as early as 2 wk after vaccination compared with the other treatment groups ( Fig. 3 A ; P < 0.05 in all tissues). Moreover, the between PD-1 and its ligands in vitro partially restored eff ector function and improved the proliferative capacity of exhausted CD8 + T cells in these chronic infections ( 14 -23 ) . Collectively, these data suggest that PD-1 signaling on T cells is a major inhibitory pathway operating during chronic infection and blockade in vivo may be useful for the treatment of chronic viral infections.
In this study, we examined whether blockade of the PD-1 pathway in combination with therapeutic vaccination could enhance CD8 + T cell immunity and resolution of a chronic infection in mice. Mice that were persistently infected with LCMV CL-13 were vaccinated with a recombinant vaccinia virus expressing the LCMV gp [33] [34] [35] [36] [37] [38] [39] [40] [41] epitope and treated with anti -PD-L1 blocking antibody. This combinatorial therapeutic vaccination synergistically enhanced epitope-specifi c CD8 + T cell responses and resulted in accelerated viral clearance. Responding CTL demonstrated increased cytokine production, increased expression of the interleukin-7 receptor-␣ (CD127) and decreased expression of PD-1, correlating with enhanced viral control. Moreover, therapeutic vaccination combined with PD-L1 blockade also enhanced CD8 + T cell responses and viral control in the absence of CD4 + T cells. Together, this provides a promising strategy for the treatment of chronic viral infections, including those that induce pronounced CD4 + T cell defi ciency, such as HIV.
RESULTS

PD-L1 blockade synergizes with therapeutic vaccination to enhance T cell immunity and clearance of persistent viral infection
To determine the eff ect of therapeutic vaccination in combination with PD-L1 blockade during chronic infection, mice were infected with LCMV CL-13. 4 wk after infection, when viral loads were between ‫ف‬ 10 3 and 10 5 PFU/ml of serum, mice were vaccinated with a recombinant vaccinia virus expressing the LCMV gp [33] [34] [35] [36] [37] [38] [39] [40] [41] CD8 + T cell epitope (VV/GP33). For the combinatorial therapeutic vaccination, mice were treated with anti -PD-L1 blocking antibody ( ␣ PD-L1) after vaccination. Control mice were vaccinated with WT vaccinia virus (VV/WT) with or without PD-L1 blockade. This experimental setting allowed us to follow antigenspecifi c CD8 + T cell responses to the therapeutic vaccine (gp33-specifi c) alongside responses to other LCMV epitopes not found within the vaccine vector (gp276-specifi c).
We longitudinally monitored individual mice for D b GP33-and D b GP276-specifi c T cell responses, as well as serum viral load in the blood after treatment. Consistent with our previous study ( 11 ) , therapeutic vaccination (VV/GP33) induced little expansion of the D b GP33-specifi c CD8 + T cell population ( Fig. 1 A ; P > 0.05, 2 wk after vaccination) and no change in gp276 responses ( Fig. 1 B ) , compared with control VV/WT vaccinated mice. PD-L1 blockade of control mice (VV/WT + ␣ PD-L1) resulted in a signifi cant increase of both D b GP33-and D b GP276-specifi c CD8 + T cell response (P < 0.01 in both, 2 wk after therapy), as previously reported ( 13 ) . combination therapy is durable to a later time point and better than PD-L1 blockade alone.
To further examine the resolution of viremia after therapeutic vaccination, we performed immunostaining on tissue sections from the spleen at 2 wk after therapy ( Fig. 3 D ) . LCMV CL-13 antigen was found in the marginal zones of the white pulp and associated with vasculature in the spleen after control VV/WT vaccination. We observed similar viral antigen staining after vaccination with VV/GP33, whereas PD-L1 blockade appeared to induce clearance from the splenic parenchyma, although antigen remained associated with vasculature. Moreover, the combination of PD-L1 blockade and therapeutic vaccination induced a noticeably greater reduction in viral antigen in the spleen. A similar pattern of viral antigen mice completely controlled viremia in spleen and liver within 4 wk after combinatorial therapeutic vaccination, whereas 70 and 60% of VV/GP33-vaccinated mice remained viremic in spleen and liver, respectively, at this time point ( Fig. 3 B ) . We also measured viral titers at a later time point (14 wk after therapy) to confi rm the effi cacy of combined therapy. The kidney is a heavy reservoir of CL-13 infection and is a good target organ to monitor long-term persistence ( 3 ) . There were high levels of virus in the kidney of CL-13 -infected mice treated with control vaccine ( Fig. 3 C ) . In contrast, mice given the combinatorial therapeutic vaccine showed a substantial decrease of virus (P < 0.01 and P < 0.05 compared with VV/WT and VV/WT + ␣ PD-L1 groups, respectively), indicating that the effi cacy of that therapeutic vaccination can improve CD8 + T cell function in an epitope-specifi c manner because IFN-␥ production and CD107a/b expression by CD8 + T cells responding to other epitopes were not increased. PD-L1 blockade induced an increase in functional CD8 + T cells responding to multiple epitopes, as previously reported ( 13 ) . Importantly, combinatorial therapeutic vaccination signifi cantly increased the proportion of IFN-␥ + CD107a/b + GP33-specifi c CD8 + T cells over that in all other groups ( Fig. 4 , A and B ; P < 0.01). An increase in IFN-␥ production responding to GP33 peptide appeared to be correlated to viral titer observed in tissues ( Fig. 3 ) , which is consistent with the study confi rming the critical role of IFN-␥ in reducing viral loads ( 24 ) . No such increase was seen in CD8 + T cells responding to other epitopes (P > 0.05).
To further determine whether combinatorial therapeutic vaccination improved CD8 + T cell function, we assessed staining was also observed in the liver in the diff erent treatment groups (Fig. S1 , available at http://www.jem.org/cgi/content/ full/jem.20071949/DC1).
Functional and phenotypic changes in exhausted CD8 + T cells after combinatorial therapeutic vaccination
We next determined whether the combination of PD-L1 blockade with therapeutic vaccine improved the function of epitope-specifi c CD8 + T cells during persistent infection. We measured the ability of virus-specifi c CTLs to produce the cytokine IFN-␥ and to degranulate by monitoring CD107a/b expression at 2 wk after therapy ( Fig. 4, A and B ) . Although therapeutic vaccination alone enhanced few D b GP33-specifi c CD8 + T cell numbers ( Fig. 2 ) , IFN-␥ production and CD107a/b expression by CD8 + T cells specifi c for GP33 was increased compared with control VV/WTvaccinated mice ( Fig. 4 , A and B ; P < 0.05). This indicates that the combination of therapeutic vaccination and PD-L1 blockade greatly improved CD8 + T cell function during chronic viral infection.
Granzyme B expression on D b GP33 + CD8 + T cells in the blood was gradually down-regulated in control VV/ WT-vaccinated mice as serum viremia decreased ( Fig. 5 A ) . The MFI of granzyme B was lower in both blood and spleen in mice treated with ␣ PD-L1, with or without therapeutic vaccination (P < 0.01). This decreased granzyme B expression was observed on D b GP276 + , as well as D b GP33 + , CD8 + T cells after PD-L1 blockade alone and combinatorial therapeutic vaccination ( Fig. 5 A ) . Importantly, PD-1 expression on GP33-specifi c CD8 + T cells was signifi cantly down-regulated in the spleen, liver, and lung in mice treated with the combinatorial vaccine, in comparison with the other groups ( Fig. 5 B ) . Decreased level of PD-1 after combinatorial therapeutic vaccination was also observed on D b GP276 + CD8 + T cells ( Fig. 5 B ) . the ability of IFN-␥ -producing CD8 + T cells to produce TNF-␣ on a per cell basis ( Fig. 4 C ) . After stimulation with GP33 peptide, but not with GP276 peptide, the population of TNF-␣ + IFN-␥ + CD8 + T cells increased in VV/GP33 vaccinated mice compared with VV/WT mice (P < 0.05). PD-L1 blockade enhanced TNF-␣ production by GP33-and GP276-specifi c CD8 + T cells (P < 0.01). Combinatorial therapeutic vaccination further improved the ability of IFN-␥ -producing CD8 + T cells to produce TNF-␣ in response to GP33 peptide (P < 0.05), but not to GP276 peptide (P > 0.05). In addition, we observed that IL-2 production specifi c to GP33 peptide was improved in the mice vaccinated with VV/GP33 + ␣ PD-L1 (20-and 2.5-fold compared with VV/WT and VV/WT + ␣ PD-L1, respectively), even though the percentage of IL-2/IFN-␥ coproducers among IFN-␥ -producing CD8 + T cells did not dramatically increase compared with that of PD-L1 blockade alone ( Fig. 4 D ) . Together, these results demonstrate The combination of therapeutic vaccine with PD-L1 blockade did not further increase this CD127 hi population. We also found that CD127 expression in other tissues including liver, lung, and LN increased after PD-L1 blockade regardless of therapeutic vaccination. However, combinatorial therapeutic vaccination did not induce CD62L expression on these cells (Fig. S3 , available at http://www.jem.org/cgi/ content/full/jem.20071949/DC1).
Collectively, reduced expression of granzyme B and PD-1 tightly correlated with reduced viral titer after combinatorial therapeutic vaccination (Fig. S2 , available at http:// www.jem.org/cgi/content/full/jem.20071949/DC1).
Exhausted CD8 + T cells generated during persistent infection display a very diff erent phenotype from long-lived memory cells. Chronically stimulated CD8 + T cells downregulate IL-7R ␣ (CD127), which is indicative of reduced responsiveness to prosurvival/homeostatic signals delivered by IL-7 ( 16, 19, 20, 25 -27 ). We observed increased expression ( Fig. 6 C ; P < 0.02) . These data suggest that the increased population of epitope-specifi c CD8 + T cells after combinatorial therapeutic vaccination may result from both increased proliferation and decreased susceptibility to cell death.
We next measured the eff ect of combinatorial therapeutic vaccination on the ability of epitope-specifi c CD8 + T cells to produce IFN-␥ and to induce degranulation in the absence of CD4 + T cell help. A signifi cant increase of IFN-␥ production and CD107a/b expression was observed after combinatorial therapeutic vaccination ( Fig. 6 D ) . Interestingly, increased degranulation was also observed in mice treated with VV/GP33 or PD-L1 blockade alone, although to a lesser extent. However, combinatorial therapy did not further improve IFN-␥ production by D b GP33 + CD8 + T cells when compared with PD-L1 blockade alone ( Fig. 6 E ) , unlike that in the presence of CD4 + T cell help ( Fig. 4 C ) . Similarly, therapeutic vaccination did not increase IFN-␥ production by CD8 + T cells compared with control vaccination. Nevertheless, the clearance of virus in these mice correlated with their degranulation capacity. Thus, we observed a signifi cant reduction in virus titer in the spleen, liver, and lung after VV/GP33 + ␣ PD-L1 treatment compared with therapeutic vaccination or PD-L1 blockade alone ( Fig. 6 F ; P < 0.05 in multiple tissues). These results demonstrate that the combination of therapeutic vaccination and PD-L1 blockade more effi ciently enhanced CD8 + T cell responses and viral control than PD-L1 blockade alone, both in CD4 + T cell help -suffi cient and -defi cient hosts.
Effect of therapeutic vaccination on antigen presentation by dendritic cells
Mice chronically infected with LCMV CL-13 contain high levels of virus in multiple tissues, and there is clearly suffi cient antigen in these mice to drive virus-specifi c T cell responses ( 29 ) , especially after blockade of the PD-1 -PD-L1 pathway ( 13 ) . It is unlikely that the amount of gp33-41 epitope expressed in vivo by the recombinant VV/GP33 would exceed the total amount of gp33-41 epitope present in the chronically infected mice. This raised the interesting question as to how therapeutic vaccination can provide synergism with PD-L1 blockade even if therapeutic vaccination itself seems to be ineff ective. Because CD8 + T cells specifi c for LCMV epitopes that were not expressed by the vaccine (i.e., D b GP276-286 tetramer-positive cells) were not boosted after therapeutic vaccination, as shown in Fig. 6 A , it is likely that vaccine-induced infl ammation alone is not suffi cient to enhance the CD8 + T cell response. Thus, we hypothesized that APCs after therapeutic vaccination can present antigen more effi ciently compared with the APCs present in the chronically infected mice. To test this, we determined whether antigen presentation by APCs is improved after therapeutic vaccination during chronic infection. DCs were isolated from Effi cacy of combinatorial therapeutic vaccination in the absence of CD4 + T cells Under such " helpless " conditions, chronic CL-13 infection leads to more pronounced exhaustion of antigen-specifi c CD8 + T cells and is relevant to persistent infections, such as HIV in humans. We examined whether the combination of therapeutic vaccination and PD-L1 blockade improved CD8 + T cell responses under conditions of CD4 + T cell defi ciency. In our CD4 helpless model, CD4 + T cells are only transiently depleted ( > 99%) using ␣ CD4 antibody (GK1.5) at the time of infection, and CD4 + T cell numbers return to nearby normal levels within a month after infection. However, although total numbers of CD4 + T cells are restored at a later time point after infection with CL-13, the virus-specifi c CD4 + T cell response is severely impaired compared with memory CD4 + T cell responses after LCMV acute infection, and is hardly recovered even after PD-L1 blockade (Fig. S4 , available at http://www.jem.org/cgi/content/full/jem.20071949/DC1), showing that this model provides a situation where CD4 + T cell help is very restricted for a long period of time. When CD4 + T cell help was absent, therapeutic vaccination with VV/GP33 alone induced expansion of epitope-specifi c CD8 + T cells ( Fig. 6 , A and B ; P < 0.01). Importantly, combinatorial therapeutic vaccination further increased the frequency of D b GP33-specifi c CD8 + T cells in helpless mice at least twofold compared with therapeutic vaccination or PD-L1 blockade alone, in both lymphoid and nonlymphoid tissues ( Fig. 6, A and B ) . The number of D b GP33 + CD8 + T cells was approximately sixfold higher in lung and threefold higher in spleen and liver, respectively, after combinatorial therapeutic vaccination ( Fig. 6 B ; P < 0.001). However, there was no diff erence in the frequency of D b GP276-specifi c CD8 + T cells between combinatorial therapeutic vaccination and ␣ PD-L1 treatment, indicating epitope-specifi c CD8 + T cell expansion by combinatorial therapeutic vaccination ( Fig. 6 A ; P > 0.05).
To examine in detail how combinatorial therapeutic vaccination increased the epitope-specifi c CD8 + T cell population, we measured the proliferation of antigen-specifi c CD8 + T cells after therapeutic vaccination by BrdU incorporation ( Fig. 6 A ) . After PD-L1 blockade, > 90% of D b GP33 + and 80% of D b GP276 + cells incorporated BrdU, as previously reported ( 13 ) . Combinatorial vaccination also induced a similar level of BrdU incorporation. These data suggested that the exhausted CD8 + T cells proliferated after PD-L1 blockade, and that this proliferation might be accelerated by simultaneous therapeutic vaccination resulting in more D b GP33-specifi c CD8 + T cells ( Fig. 6, A and B ) .
Increased expression of PD-1 on CD8 + T cells during chronic infection is also known to be associated with susceptibility to apoptosis upon antigen-specifi c TCR stimulation ( 22, 28 ) . We found that PD-L1 blockade reduced the frequency of Annexin V + propidium iodide (PI) + apoptotic cells (P < 0.01), as well as cells in the early stages of apoptosis (Annexin V + PI Ϫ , P < 0.02) and increased numbers of viable Annexin V -PI -cells ( Fig. 6 C ) . This indicated that this treat-vaccination could present antigen more effi ciently than the DCs present in the CL-13 -infected mice. These results suggest that the mechanism of synergism between therapeutic vaccination and PD-L1 blockade could be that DCs can effi ciently present epitopes encoded by therapeutic vaccination and subsequently reinforce the proliferation of antigenspecifi c CD8 + T cells restored by ␣ PD-L1 treatment.
spleens of LCMV CL-13 -infected mice vaccinated with VV/WT or VV/GP33 and co-cultured with CFSE-labeled naive P14 CD8 + T cells (D b GP33-41 -specifi c; Fig. 7 A ) . DCs from mice given the therapeutic vaccine (VV/GP33) were able to induce more proliferation of P14 cells compared with DCs from the chronically infected mice given VV/WT ( Fig. 7 B ) . These data demonstrate that DCs generated after therapeutic ity, emergence of drug resistance mutations, and rebounding viremia after cessation of antiviral therapy ( 32 -34 ) . In these circumstances, our approach using ␣ PD-L1 might minimize a deleterious eff ect on T cells, maximizing a therapeutic effect. As shown in our results, therapeutic vaccination most effi ciently boosted epitope-specifi c CD8 + T cells when combined with PD-L1 blockade. Expansion of epitope-specifi c CD8 + T cells and accelerated control of virus were also observed in multiple tissues in epitope-specifi c manner, indicating that the eff ectiveness of combinatorial therapeutic vaccination is valid systemically. Such an approach could be more eff ective in reducing viral load when multiple epitopes are introduced to therapeutic vaccine vector.
Recent studies of HIV infection showed that PD-1 is signifi cantly up-regulated on HIV-specifi c CD8 + T cells in blood ( 14 -17 ) . Furthermore, the proportion of CD8 + T cells expressing PD-1 and the levels of PD-1 on HIV-specifi c T cells strongly correlated with viral load in the blood plasma ( 14, 16 ) . Antiretroviral treatment resulted in the dramatic decline of plasma viral load, coincident with a decrease in the level of PD-1 expression on HIV-specifi c CD8 + T cells ( 14, 16 ) . Similarly, Urbani et al. showed that although PD-1 declined on HCV-specifi c CD8 + T cells during recovery, its expression remained high when HCV persisted ( 20 ) . Thus, PD-1 expression level appears to be a good indicator of viral load and disease progression during persistent infection. In this study, we show decreased PD-1 expression on antigenspecifi c CD8 + T cells after combinatorial therapeutic vaccination, which correlated with viral control. PD-1 was also down-regulated on D b GP276 + as well as D b GP33 + CD8 + T cells, suggesting that down-regulation of PD-1 occurred as a consequence of viral control. Nevertheless, PD-1 expression on gp33-specifi c CD8 + T cells in diff erent tissues was not always proportional to virus titer, suggesting that other factors in the tissue environment may also aff ect PD-1 expression on T cells.
PD-1 expression is also associated with altered survival and expansion of HIV-specifi c cells ( 14 -16 ) . We show that combinatorial therapeutic vaccination induced lower numbers of Annexin V + gp33-specifi c T cells, suggesting reduced susceptibility to apoptosis and enhanced survival. During chronic LCMV infection, antigen-specifi c CD8 + T cells demonstrate reduced responses to the homeostatic cytokine IL-7, and an increased dependence upon antigenic signals for survival ( 29 ) . Recent studies also demonstrate that downregulation of CD127 occurs on LCMV-, HIV-, and HCVspecifi c CD8 + T cells ( 19, 27, 35 ) . Interestingly, CD127 was found to be up-regulated on a population of antigen-specifi c CD8 + T cells after PD-L1 blockade and combinatorial therapeutic vaccination, suggesting that CD8 + T cell diff erentiation was altered after treatment. Functional programming of T cells during persistent infection appears to be an ongoing event, rather than restricted to signals acquired during priming ( 36 ) . Collectively, our data suggest that combinatorial therapeutic vaccination generated CD8 + T cells with improved phenotype and function.
DISCUSSION
The goal of therapeutic vaccination is to enhance adaptive immune responses during persistent infection and to reduce the viral burden. However, such strategies are often hampered by the reduced responsiveness and low proliferative potential of antigen-specifi c T cells ( 11 ) , suggesting the need for alternative strategies to enhance immune function during chronic infection. In this study, we evaluated the effi cacy of therapeutic vaccination in combination with blockade of the inhibitory PD-1 pathway, which plays a role in T cell exhaustion during chronic viral infection. Administration of a therapeutic vaccine in combination with PD-L1 blockade enhanced expansion and improved the function of epitopespecifi c CD8 + T cells in mice persistently infected with LCMV CL-13. This combinatorial therapeutic vaccination accelerated viral control compared with therapeutic vaccine only or PD-L1 blockade alone. These results defi ne a novel strategy for eff ective therapeutic vaccination of chronic viral infections.
When viral load is high and T cell dysfunction is severe, therapeutic vaccination alone is unlikely to be highly beneficial ( 11 ) . Indeed, poor responses have been reported for the therapeutic vaccination of human HBV carriers ( 8 ) . Conversely, at lower viral loads, when T cell exhaustion is less severe, therapeutic vaccination may be more eff ective ( 11 ) . Studies with nonhuman primates support this concept because therapeutic vaccination is more eff ective after antiviral therapy of SIV replication ( 30, 31 ) . Although suppression of chronic viral replication using antiviral drugs causes a corresponding increase of T cell activity, it can involve drug toxic- 
MATERIALS AND METHODS
Mice and infections. 4 -6-wk-old female C57BL/6 mice were purchased from The Jackson Laboratory. For infection, mice received 2 × 10 6 PFU of LCMV CL-13 i.v. LCMV titers were determined by plaque assays, as described previously ( 11 ) . All mice were used in accordance with National Institutes of Health and the Emory University Institutional Animal Care and Use Committee guidelines.
In vivo antibody blockade and therapeutic vaccination. For therapeutic vaccination, 2 × 10 6 PFU of VV/GP33 as therapeutic vaccine or VV/WT as control vaccine was given i.p., as described previously ( 11 ) . For PD-L1 blockade, 200 μ g of rat anti -mouse PD-L1 antibody (10F:9G2) or rat IgG2b isotype control were administered i.p. 5 times every 3 d, beginning on the day of vaccination. For depletion of CD4 + T cells, mice were given 500 μ g of anti -mouse CD4 antibody (GK1.5; BioExpress) i.p. on days Ϫ 1 and 0 after infection with CL-13.
Cell isolation and in vitro proliferation assay. Lymphocytes were isolated from tissues including spleen, liver, lung, inguinal LN, and blood, as previously described ( 13 ) . Liver and lung were perfused with ice-cold PBS before removal for lymphocyte isolation. For DC isolation, spleen was digested in complete media containing 1 mg/ml collagenase type II (Worthington Biochemicals) and 1 mg/ml DNase (Sigma-Aldrich) as previously described ( 47 ) . DCs were enriched using CD11c beads (Miltenyi Biotec). To measure the ability of antigen presentation by DCs, 5 × 10 5 P14 Thy1.1 + CD8 + T cells labeled with CFSE were cultured with 2.5 × 10 4 DCs. Proliferation was determined by fl ow cytometry after 3 or 5 d in culture.
Antibodies and fl ow cytometry. MHC class I tetramers were generated and used as previously described ( 3 ). All antibodies were obtained from BD Biosciences except for granzyme B (Caltag Laboratories) and CD127 (eBioscience). All surface and intracellular cytokine staining was performed as previously described ( 3 ). To detect degranulation, splenocytes were stimulated for 5 h in the presence of brefeldin, monensin, anti -CD107a-FITC, and anti -CD107b-FITC. For in vivo BrdU incorporation, CL-13 -infected mice were fed 1 mg/ml BrdU in their drinking water every day for 2 wk from the time point of therapeutic vaccination. Intracellular staining with a BrdUspecifi c antibody was performed as previously described ( 48 ) . For analysis of direct ex vivo apoptosis, splenocytes were isolated and briefl y incubated with Annexin V and PI as previously described ( 48 ) .
Confocal microscopy. Spleens were removed from mice and frozen in OCT (TissueTek). 20-μ m cryostat sections were fi xed in ice-cold acetone for 10 min. Sections were stained with ER-TR7 antibody (Biogenesis) and goat anti -rat Alexa Fluor 488 (Invitrogen) to detect reticular cells, and with polyclonal anti-LCMV guinea pig sera plus goat anti -guinea pig Alexa Fluor 568 (Invitrogen). Sections were analyzed by confocal microscopy (LSM510 Meta; Carl Zeiss, Inc.). Images were prepared using ImageJ (National Institutes of Health) and Photoshop (Adobe).
Quantitative real-time RT-PCR. Sequences of PCR primer pairs for IL-10 and HPRT are as follows: IL-10 (forward, 5 Ј -GGTTGCCAAGCCTTATC-GGA-3 Ј ; reverse, 5 Ј -ACCTGCTCCACTGCCTTGCT-3 Ј ) and HPRT (forward: 5 Ј -AGGTTGCAAGCTTGCTGGT-3 Ј ; reverse, 5 Ј -TGAAGTAC-TCATTATAGTCAAGGGCA-3 Ј ). Total RNA were extracted from whole spleens using RNeasy mini kit (QIAGEN), and then reverse transcribed by Superscript II (Invitrogen). Real-time quantitative RT-PCR for IL-10 mRNA using SYBR Green (Applied Biosystems) and detected using an iCycler (Bio-Rad Laboratories) as previously described ( 47 ) . IL-10 expression was quantifi ed, using HPRT as a reference, by the comparative C T method, as per the manufacturer ' s instructions (Applied Biosystems).
Statistical analysis. Statistical analysis was performed with two-tailed unpaired Student ' s t tests using Prism (GraphPad Software, Inc.).
We also demonstrate that DCs generated after therapeutic vaccination with VV/GP33 provide critical positive signals that can now synergize with blocking PD-1-mediated negative signals. It is worth noting that these positive signals from DCs require the generation of new peptides from the therapeutic vaccine and are not simply caused by some infl ammation induced by the VV infection because (a) the response specifi c to D b GP276-286 epitope was not changed after VV/GP33 therapeutic vaccination and (b) LCMV-specifi c CD8 + T cells were not aff ected by vaccination with wildtype vaccinia virus. Indeed, there was no diff erence in the levels of infl ammatory cytokines (i.e., TNF-␣ , IFN-␥ , MCP-1, and IL-10) after vaccination with VV/WT or VV/GP33 (unpublished data).
Though therapeutic vaccination alone is not suffi cient to boost the ongoing CD8 + T cell responses caused by the abundance of immunosuppressive signals, blockade of such signals may be enough to tip the balance toward positive amplifi cation of the response. Based on this original concept, it would be interesting to block other immunosuppressive factors in combination with therapeutic vaccination. IL-10 blockade is one potential candidate because IL-10 is elevated during LCMV, HIV, HCV, and HBV infections ( 37 -41 ) and its blockade can improve viral clearance ( 42, 43 ) . We also observed that IL-10 mRNA levels are elevated around twofold in the mice chronically infected and vaccinated, compared with the naive mice ( ( 44 ) . Thus, their study, along with ours, establishes that blocking immune inhibitory signals might overcome the failure of current therapeutic vaccination strategies to treat persistent viral infections. Interestingly, in vivo PD-L1 blockade does not seem to aff ect IL-10 level during chronic infection (Fig. S5) , even though PD-1/PD-L1 blockade has been reported to down-regulate IL-10 but up-regulate IL-2 and IFN-␥ during in vitro stimulation ( 45, 46 ) . These data suggest that inherent suppression on exhausted T cells by PD-1 and environmental suppression by IL-10 might be regulated independently. Thus, it would be interesting to test the eff ect of synergism between PD-1 blockade and IL-10 blockade on the induction of CD8 + T cell response during chronic infection.
In summary, our study shows that therapeutic vaccination during chronic viral infection, in combination with PD-L1 blockade, synergistically boosts epitope-specifi c CD8 + T cell responses and promotes viral control. These experiments demonstrate that blocking this major inhibitory pathway during chronic infection improves the effi cacy of therapeutic vaccination. This strategy may prove useful for the treatment of persistent infections, in general, as well as to improve immune responses to tumors.
Online supplemental material. Fig. S1 provides immunostaining data of liver with ERTR7 (green) and ␣ LCMV antigens (red) at 2 wk after therapy. Fig. S2 displays a correlation between virus titer and granzyme B/PD-1 expression. Fig. S3 shows CD62L expression on antigen-specifi c CD8 + T cells after combinatorial therapeutic vaccination. Fig. S4 shows that there is no induction of antigen-specifi c CD4 + T cell immune response during chronic infection when CD4 + T cells are depleted at the same time of infection. Fig. S5 demonstrates no change of IL-10 mRNA level after therapeutic vaccination and/or ␣ PD-L1 treatment. The online version of this article is available at http://www.jem.org/cgi/content/full/jem.20071949/DC1.
